Abstract
The challenge in developing an anti-cocaine vaccine is that cocaine is a small molecule, invisible to the immune system. Leveraging the knowledge that adenovirus (Ad) capsid proteins are highly immunogenic in humans, we hypothesized that linking a cocaine hapten to Ad capsid proteins would elicit high-affinity, high-titer antibodies against cocaine, sufficient to sequester systemically administered cocaine and prevent access to the brain, thus suppressing cocaine-induced behaviors. Based on these concepts, we developed dAd5GNE, a disrupted E1-E3- serotype 5 Ad with GNE, a stable cocaine analog, covalently linked to the Ad capsid proteins. In pre-clinical studies, dAd5GNE evoked persistent, high titer, high affinity IgG anti-cocaine antibodies, and was highly effective in blocking cocaine-induced hyperactivity and cocaine self-administration behavior in rats. Future studies will be designed to expand the efficacy studies, carry out relevant toxicology studies, and test dAd5GNE in human cocaine addicts.
Keywords: dAd5GNE, Cocaine, Addiction, Adenovirus, Vaccine, Anti-coccaine antibody, passive immunity, keyhole limpet hemocyanin, EDC, E1-E3-, Sensory nerve action potential, Palmitoylethanolamide, Laser evoked potential
CNS & Neurological Disorders - Drug Targets
Title: Anti-Cocaine Vaccine Based on Coupling a Cocaine Analog to a Disrupted Adenovirus
Volume: 10 Issue: 8
Author(s): George Koob, Martin J. Hicks, Sunmee Wee, Jonathan B. Rosenberg, Bishnu P. De, Stephen M. Kaminksy, Amira Moreno, Kim D. Janda and Ronald G. Crystal
Affiliation:
Keywords: dAd5GNE, Cocaine, Addiction, Adenovirus, Vaccine, Anti-coccaine antibody, passive immunity, keyhole limpet hemocyanin, EDC, E1-E3-, Sensory nerve action potential, Palmitoylethanolamide, Laser evoked potential
Abstract: The challenge in developing an anti-cocaine vaccine is that cocaine is a small molecule, invisible to the immune system. Leveraging the knowledge that adenovirus (Ad) capsid proteins are highly immunogenic in humans, we hypothesized that linking a cocaine hapten to Ad capsid proteins would elicit high-affinity, high-titer antibodies against cocaine, sufficient to sequester systemically administered cocaine and prevent access to the brain, thus suppressing cocaine-induced behaviors. Based on these concepts, we developed dAd5GNE, a disrupted E1-E3- serotype 5 Ad with GNE, a stable cocaine analog, covalently linked to the Ad capsid proteins. In pre-clinical studies, dAd5GNE evoked persistent, high titer, high affinity IgG anti-cocaine antibodies, and was highly effective in blocking cocaine-induced hyperactivity and cocaine self-administration behavior in rats. Future studies will be designed to expand the efficacy studies, carry out relevant toxicology studies, and test dAd5GNE in human cocaine addicts.
Export Options
About this article
Cite this article as:
Koob George, J. Hicks Martin, Wee Sunmee, B. Rosenberg Jonathan, P. De Bishnu, M. Kaminksy Stephen, Moreno Amira, D. Janda Kim and G. Crystal Ronald, Anti-Cocaine Vaccine Based on Coupling a Cocaine Analog to a Disrupted Adenovirus, CNS & Neurological Disorders - Drug Targets 2011; 10 (8) . https://dx.doi.org/10.2174/187152711799219334
DOI https://dx.doi.org/10.2174/187152711799219334 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aripiprazole in Children and Adolescents with Schizophrenia
Current Psychopharmacology Risk Profiles in Type 2 Diabetes (Metabolic Syndrome): Integration of IL-10 Polymorphisms and Laboratory Parameters to Identify Vascular Damages Related Complications
Current Pharmaceutical Design A Review of Eugenol-based Nanomedicine: Recent Advancements
Current Bioactive Compounds Delivery of Curcumin and Medicinal Effects of the Copper(II)-Curcumin Complexes
Current Pharmaceutical Design Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Diagnosis of Alterations of Serum Calcium Metabolism
Medicinal Chemistry Patent Selections:
Recent Patents on Computer Science Fragile X Syndrome and Alzheimers Disease: Another Story About APP and β -Amyloid
Current Alzheimer Research Molecular Mechanisms of Anti-Inflammatory Activity Mediated by Flavonoids
Current Medicinal Chemistry Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson’s Disease
Current Neuropharmacology Glyceraldehyde-3-phosphate Dehydrogenase from Chironomidae Showed Differential Activity Towards Metals
Protein & Peptide Letters Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
Current Medicinal Chemistry Isolation and Quantification of Chemical Marker of Polygonatum verticillatum: First Report
Current Traditional Medicine RNAi-based Gene Therapy for Dominant Limb Girdle Muscular Dystrophies
Current Gene Therapy Design and Development of ChemInfoCloud: An Integrated Cloud Enabled Platform for Virtual Screening
Combinatorial Chemistry & High Throughput Screening The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Citrullinated Peptides in the Diagnosis of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Organic Lesions in the Brain MRI of Children with Febrile Seizure
Current Medical Imaging Design, Synthesis, Characterization, Molecular Docking, ADME Properties and <i>In Vivo</i> Antipsychotic Activity of Aripiprazole Related Drugs Candidates
Letters in Drug Design & Discovery The Possible Involvement of NMDA Glutamate Receptor in the Etiopathogenesis of Bipolar Disorder
Current Pharmaceutical Design